ethyl 5-chloro-7-methyl-1H-indole-2-carboxylate | 15936-71-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: ethyl 5-chloro-7-methyl-1H-indole-2-carboxylate
• 英文别名: 5-chloro-7-methyl-indole-2-carboxylic acid ethyl ester；5-chloro-7-methyl-1H-indole-2-carboxylic acid ethyl ester；5-Chlor-7-methyl-indol-2-carbonsaeureethylester
• CAS: 15936-71-7
• 化学式: C₁₂H₁₂ClNO₂
• 分子量: 237.686
• InChiKey: SJRZGOYZIYIJQZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  42.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P264,P280,P302+P352+P332+P313+P362+P364,P305+P351+P338+P337+P313
• 危险性描述：
  H315,H319
• 储存条件：
  2-8℃

反应信息

• 作为反应物：
  描述：

  ethyl 5-chloro-7-methyl-1H-indole-2-carboxylate 在 lithium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 16.0h， 生成 5-chloro-7-methyl-1H-indole-2-carboxylic acid
  参考文献：
  名称：

  Detailed structure–activity relationship of indolecarboxamides as H4 receptor ligands

  摘要：

  A series of 76 derivatives of the indolecarboxamide 1 were synthesized, which allows a detailed SAR investigation of this well known scaffold. The data enable the definition of a predictive QSAR model which identifies several compounds with an activity comparable to 1. A selection of these new H4R antagonists was synthesized and a comparison of predicted and measured values demonstrates the robustness of the model (47-55). In addition to the H-4-receptor activity general CMC and DMPK properties were investigated. Some of the new analogs are not only excellently soluble, but display a significantly increased half-life in mouse liver microsomes as well. These properties qualify these compounds as a possible new standard for future in vivo studies (e.g 51, 52 and 55). Moreover, the current studies also provide valuable information on the potential receptor ligand interactions between the indolcarboxamides and the H4R protein. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.06.016
• 作为产物：
  描述：

  (E)-ethyl 2-(2-(4-chloro-2-methylphenyl)hydrazono)propanoate 在 amberlyst 15 作用下， 以 甲苯 为溶剂， 以50%的产率得到ethyl 5-chloro-7-methyl-1H-indole-2-carboxylate
  参考文献：
  名称：

  Substituted Indoles

  摘要：

  该发明提供了以下式（I）的化合物 其中R 1 ，R 2 ，R 3 ，R 4 ，R 5 和R 6 具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物在治疗由SUV420H1介导和调节的疾病和症状中作为药剂是有用的。还提供了由一个或多个式（I）化合物组成的药物组合物。

  公开号：

  US20170174688A1

文献信息

• SPIRO-PIPERIDINE DERIVATIVES
  申请人：Bissantz Caterina

  公开号：US20080139553A1

  公开（公告）日：2008-06-12

  The present invention is concerned with novel indol-2-yl-carbonyl-spiro-piperidine derivatives as V1 a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of anxiety, depressive disorders and other diseases. The compounds of present invention are represented by the general formula (I) wherein R 1 to R 1 , X and Y are as defined in the specification.

  本发明涉及作为V1a受体拮抗剂的新型吲哚-2-基-羰基-螺环哌啶衍生物，其制备方法，含有它们的药物组合物以及它们用于治疗焦虑、抑郁症和其他疾病的用途。本发明的化合物由通式（I）表示，其中R1至R1、X和Y如规范中所定义。
• INDOLES
  申请人：Bissantz Caterina

  公开号：US20080139548A1

  公开（公告）日：2008-06-12

  The present invention is concerned with novel indol-2-yl-carbonyl-piperidin-benzoimidazolon and indol-2-yl-carbonyl-piperidin-benzoxazolon derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of anxiety and depressive disorders and other diseases. In particular, the present invention concerns compounds of formula (I) wherein R 1 to R 11 , X and Y are as defined in the specification.

  本发明涉及新颖的吲哒-2-基-羰基-哌啶-苯并咪唑酮和吲哒-2-基-羰基-哌啶-苯并噁唑酮衍生物作为V1a受体拮抗剂，它们的制备，含有它们的药物组合物以及它们用于治疗焦虑和抑郁症及其他疾病。具体而言，本发明涉及式(I)的化合物，其中R1至R11，X和Y如规范中定义。
• Indoles
  申请人：Bissantz Caterina

  公开号：US20080269290A1

  公开（公告）日：2008-10-30

  The present invention is concerned with novel indol-2-yl-carbonyl-piperidin-benzoimidazolon and indol-2-yl-carbonyl-piperidin-benzoxazolon derivatives as V1 a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of anxiety and depressive disorders and other diseases. In particular, the present invention concerns compounds of formula (I) wherein R 1 to R 11 , X and Y are as defined in the specification.

  本发明涉及新型的indol-2-yl-carbonyl-piperidin-benzoimidazolon和indol-2-yl-carbonyl-piperidin-benzoxazolon衍生物，作为V1a受体拮抗剂，它们的制造，包含它们的制药组合物以及它们用于治疗焦虑和抑郁症以及其他疾病的用途。特别地，本发明涉及式(I)中R1到R11、X和Y所定义的化合物。
• Spiro-piperidine derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US08202993B2

  公开（公告）日：2012-06-19

  The present invention is concerned with novel indol-2-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of anxiety, depressive disorders and other diseases. The compounds of present invention are represented by the general formula (I) wherein R1 to R1, X and Y are as defined in the specification.

  本发明涉及新型的indol-2-yl-carbonyl-spiro-piperidine衍生物作为V1a受体拮抗剂，它们的制造，含有它们的药物组合物以及它们用于治疗焦虑，抑郁症和其他疾病的用途。本发明的化合物由一般式（I）表示，其中R1到R1，X和Y如规范中所定义。
• INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP2089381A1

  公开（公告）日：2009-08-19